Pronovost A D, Lucia H L, Dann P R, Hsiung G D
J Infect Dis. 1982 Jun;145(6):904-8. doi: 10.1093/infdis/145.6.904.
The chemotherapeutic efficacy of acyclovir was evaluated in guniea pigs that were inoculated intravaginally with herpes simplex virus type 2 (HSV-2). Acyclovir was administered systemically (50 mg/kg of body weight per day ip) beginning three days after inoculation and continuing for 10-11 days. Treatment with acyclovir reduced the incidence of paralysis of the hind limbs, mortality, and the severity and duration of genital lesions but had little effect on the excretion of virus from the genital tract. Recovery of HSV-2 from neural tissues of infected animals during latent infection was less frequent in acyclovir-treated animals than in untreated ones. These data suggest that acyclovir may be a promising drug for altering the severity of clinical genital herpes in humans during acute infection and reducing the incidence of viral latency following primary infection.
在经阴道接种2型单纯疱疹病毒（HSV-2）的豚鼠中评估了阿昔洛韦的化疗效果。接种三天后开始全身性给予阿昔洛韦（每天腹腔注射50mg/kg体重），持续10-11天。阿昔洛韦治疗降低了后肢麻痹的发生率、死亡率以及生殖器病变的严重程度和持续时间，但对生殖道病毒排泄几乎没有影响。与未治疗的动物相比，接受阿昔洛韦治疗的动物在潜伏感染期间从感染动物神经组织中恢复HSV-2的频率较低。这些数据表明，阿昔洛韦可能是一种有前景的药物，可用于改变人类急性感染期间临床生殖器疱疹的严重程度，并降低原发性感染后病毒潜伏的发生率。
